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Abstract Micafungin is a selective inhibitor of the syn-
thesis of fungal 1,3-b-D-glucan, an essential component of
the fungal cell wall. It is available as a powder for infusion
only and is registered for the treatment of invasive and
esophageal candidiasis in addition to prophylaxis of Can-
dida infections in both adults and children. Average
exposure after a single intravenous 100 mg dose in healthy
adults is 133 mg h/L. Both exposure and maximum plasma
concentration show linear dose proportional pharmacoki-
netics (PK) over a 0.15–8 mg/kg dose range. In healthy
adults, the clearance (CL) is 10.4 mL/h/kg and volume of
distribution is 0.2 L/kg; both are independent of the dose.
Micafungin is metabolized by arylsulfatase, catechol-O-
methyltransferase, and several cytochrome P450 (CYP)
isoenzymes (3A4, 1A2, 2B6 and 2C), but no dose adjust-
ments are necessary in patients with (severe) hepatic dys-
function. Exposure to micafungin is lower in hematology
patients, and is even further lowered in critically ill patients
(including burn patients) compared with healthy volun-
teers, which might have consequences for treatment effi-
cacy. In children, an increased CL has been reported:
40–80 mL/h/kg in premature neonates and 20 mL/h/kg in
children [4 months of age. Therefore, relatively higher
doses of 4–10 mg/kg in premature neonates and 2–4 mg/kg
in children with invasive candidiasis are used. However,
these higher CLs may also be explained by the eightfold
higher free fraction of unbound micafungin in premature
neonates, meaning that an augmented dose might not be
required.
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Key Points
Micafungin is a selective inhibitor of 1,3-b-D-glucan
synthesis and effectively inhibits the production of
the fungal cell wall.
Human cells do not have a cell wall, nor do their
cells contain 1,3-b-D-glucan. This explains the good
tolerability of echinocandins, even at a high dose.
Micafungin has linear dose proportional PK over a
dose range of 0.15–8 mg/kg.
Exposure to micafungin is considerably lower in
critically ill patients, including burn patients. These
patients could benefit from an augmented dose of
micafungin 150–200 mg.
The clearance of micafungin is much higher in
neonates and older children and these populations
receive a considerably higher weight-corrected dose
than adults.
High-dose micafungin is a candidate for less
frequent dosing (i.e. 200 mg every 48 h, or 300 mg
every 72 h) due to its favorable toxicity profile and a
possible post-antifungal effect, as well as practical
reasons.
1 Introduction
Micafungin is one of three currently available echinocan-
dins that are first-line treatment options in candidiasis and
candidemia. Along with caspofungin and anidulafungin,
micafungin is indicated for the treatment of both invasive
and esophageal candidiasis in addition to prophylaxis of
Candida infections that are frequently seen in immuno-
compromised patients [1]. In high-risk populations, such as
patients treated with chemotherapy or other immunosup-
pressive agents, and critically ill patients in the intensive
care unit, invasive Candida infections remain an important
cause of mortality and morbidity, with reported Candida-
associated mortality rates of between 20 and 60% [2–4].
Echinocandins outperform azole antifungal agents when it
comes to treatment outcome of invasive candidiasis or
candidemia and are recommended as first-line treatment for
both critically and non-critically ill patients [5–8].
Micafungin (Mycamine, FK463) is a water-soluble,
semisynthetic lipopeptide that is synthesized by chemical
modification of a fermentation product from Coleophoma
empetri [9]. It selectively inhibits the synthesis of 1,3-b-D-
glucan, an essential component of the fungal cell wall. Con-
tinued synthesis of 1,3-b-D-glucan is crucial in maintaining
fungal cell wall integrity, and inhibition leads to osmotic
instability, eventually resulting in cell lysis. Fungicidal
activity is seen in the majority of Candida species, with low
in vitro minimum inhibitory concentrations (MICs) for C.
albicans, C. glabrata and C. tropicalis, and relatively higher
MICs for C. krusei and C. parapsilosis [10]. Fungistatic
activity was seen in Aspergillus species where echinocandins
specifically show effects during active cell growth of the
hyphae, leading to damage of these structures [11]. In a neu-
tropenic rabbit model for pulmonary aspergillosis, this
activity led to decreased blood vessel invasion, prevention of
pulmonary injury, and improvement of survival compared
with untreated controls [12]. Micafungin is not active against
Cryptococcus neoformans despite the fact that its cell wall
contains 1,3-b-D-glucan, and also shows little activity against
Fusarium spp. and zygomycetes [13].
Micafungin was first approved in Japan in late 2002 and
by the US FDA in March 2005, followed by several Asian
countries between 2005 and 2007 and in the EU in April
2008 [9]. It is available as a powder for intravenous solu-
tion and recommended doses are 50–200 mg/day for
patients weighing 40 kg or more and 1–4 mg/kg/day for
children[4 months of age with a weight below 40 kg. For
children\4 months of age, including preterm neonates, a
dose of 4–10 mg/kg/day is registered for the treatment of
invasive candidiasis. A loading dose is not required [1].
This review discusses the clinical pharmacology of
micafungin in adult and pediatric patients, including
pharmacokinetics (PK), pharmacodynamics (PD), special
patient populations, and future perspectives in terms of
prospective and upcoming clinical trials. The method used
in this review can be found in the electronic supplementary
material.
2 Pharmacokinetics (PK) in Adults Patients
Micafungin is a large molecule with a molar mass of
1270.28 g/mol. Although oral bioavailability of mica-
fungin has not been reported, it is predicted to be poor
analogous to anidulafungin, which has a similar molar
mass and bioavailability of 2–7% [14]. Due to the expected
poor bioavailability, micafungin is only intended for par-
enteral use. Linear PK have been shown over a dose
ranging between 0.15 and 8 mg/kg/day, corresponding to
doses of 12.5–869 mg/day [1, 15–18].
2.1 PK in Healthy Subjects
The PK in healthy subjects has been investigated in both
single- and repeated-dose studies [19–24]. Table 1 shows
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the PK parameters and weighted averages. After a 100 mg
single dose infused in 60 min, typical values for maximum
plasma concentration (Cmax) of 9.1 mg/L, trough plasma
concentration 24 h after dosing (C24h) of approximately
2 mg/L, area under the concentration–time curve (AUC)
from zero to infinity (AUC?) of 133 mg h/L, clearance
(CL) of 10.4 mL/h/kg, apparent volume of distribution (Vd)
of 0.2 L/kg, and terminal half-life (t) of 15.4 h were
found. Additionally, after a daily 150 mg dose infused in
60 min, Cmax values after a single dose and at steady state
of 12 and 16 mg/L were achieved, respectively; C24h after
a single dose and at steady state was approximately 2.5 and
4.5 mg/L, respectively; and AUC from zero to 24 h
(AUC24) after a single dose and at steady state of 116 and
181.5 mg h/L, respectively, were reported.
In a repeated-dose study in healthy volunteers, HIV
patients and hematology patients receiving micafungin
50–150 mg daily, the drug was found to show accumula-
tion in the body over time, with a ratio of approximately
1.5 [23, 25, 26]. This accumulation factor describes the
elimination of micafungin from the body in relation to the
dose interval, meaning that for micafungin administered
daily, the AUC24 at steady state was approximately 1.5-
fold greater than the AUC24 after a single dose.
2.2 Distribution
In HIV patients with esophageal candidiasis treated with an
intravenous dose of micafungin ranging from 50 to
150 mg/day, the Vd was approximately 0.4 L/kg, with the
Vd after a single dose being similar to the Vd at steady state,
indicating that equilibrium between plasma and tissue is
rapidly reached [15]. Steady state is reached after
approximately 4–5 days. Micafungin is highly protein
bound in plasma (99.8%), mainly to albumin and a-1-acid
glycoprotein, which is concentration-independent over a
range of 10–100 mg/L [9]. At clinically relevant concen-
trations, binding to albumin was shown to be non-com-
petitive, did not displace albumin-bound bilirubin, and
showed no interaction with other protein-bound medication
[9]. Micafungin is not significantly taken up by red blood
cells, with a cell/plasma ratio of 0.7. Intracellular concen-
trations of micafungin in peripheral blood mononuclear
cells and polymorphonuclear leukocytes were approxi-
mately tenfold higher compared with corresponding
plasma concentrations [27].
2.3 Tissue Penetration
Distribution into tissues throughout the body has not been
extensively investigated and data mainly come from a
limited number of case reports [28–38]. Furthermore, these
data are often difficult to interpret because homogenate
samples may show incorrect concentrations due to differ-
ences between intra- and extracellular concentrations.
Also, an unusually high number of mononuclear cells due
to a local infection could lead to an overestimation of
extracellular micafungin concentration [39]. However,
some more easily accessible compartments can give a good
estimation of tissue penetration, such as measurements in
cerebrospinal fluid (CSF) and epithelial lining fluid (ELF).
Tissue penetration of micafungin in relation to other anti-
fungal agents has been thoroughly reviewed previously
[39]. Penetration differs per organ system and a detailed
description of available data is provided below.
The penetration of micafungin in burn eschar tissue has
been reported in several publications [40–43]. Asensio
et al. reported an average tissue (T)/Cmax ratio of 0.08,
1–3 h after administration of 100 mg on day 5 of therapy
[40], while two investigations by Sasaki et al. examined
tissue 24 h after a 200–300 mg dose and reported tis-
sue/plasma (T/P) ratios ranging from 2.2 to 6.5 in one
patient and from 0.76 to 2.32 in three other patients
[42, 43].
Penetration in the lung, specifically the ELF and alve-
olar cells (AC) was investigated in two prospective studies,
with a total of 35 volunteers receiving micafungin 150 mg
[44, 45]. The T/P ratios changed over time and ranged from
0.01 to 1.1 for ELF/P and 0.61 to 7.62 for AC/P. By
modeling and simulation, the authors predicted a mean
AUC ratio from days 1 to 14 of 1.3 for ELF/P and 3.5 for
AC/P [44, 45]. In two other patients, micafungin reached
lower concentrations in pleural fluid, with an average T/
P of 0.14 at steady state 2–4 h after dosing [46]. In another
patient, T/P ratios of 0.57 (day 29) and 0.67 (day 43) were
seen 22 h after the last dose [32].
Peritoneal fluid concentrations were assessed in 10
postsurgical patients receiving micafungin 100 mg daily.
Samples were taken at seven time points on days 1 and 3.
On both days, the AUC T/P ratio was between 0.3 and 0.4
[47] and the penetration was shown to be twice as high as
previously reported in a patient, with an ascites/plasma
ratio of 0.15 [46].
Similar to the other echinocandins, micafungin pene-
trates poorly into brain and CSF. The CSF/P ratio found in
three patients 2–5 h after administration varied widely,
with values ranging between 0.002 and 0.73 [36, 46]. In
another patient, brain tissue was obtained which contained
a T/P ratio for micafungin of 0.18 [30]. The most recent
study measured micafungin concentrations in nine samples
of three premature neonates after a 10 mg/kg dose and
measured between 1 and 1.5 mg/L, corresponding with a
CSF/C24h ratio of 0.16, and CSF/Cmax ratio of 0.04
[38, 48]. Although highly variable, these data might indi-
cate that there is sufficient penetration of micafungin in
these compartments for an antifungal effect, specifically in
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neonates with Candida meningoencephalitis treated with a
high dose.
Low penetration of micafungin was seen intraocularly
after intravenous infusion. Eight patients with Candida
endophthalmitis were described, with mean aqueous and
vitreous humor-to-plasma ratios of 0.0043 and 0.0046,
respectively [33–35]. In one patient, the tissue concen-
tration of other structures in the eye were also measured
and penetration was much better compared with
intraocular penetration, with T/P ratios of 0.094 in the
cornea, 0.86 in irises, 0.071 in retinas, and 0.34 in
choroids [34].
Distribution of micafungin to the bladder is known to
be poor, with \1% unchanged micafungin excreted in
urine. Despite this finding, some cases are reported
where micafungin was successfully used for the treat-
ment of candiduria [28, 29, 37, 49]. This might be due
to the excellent penetration of micafungin in the kidney.
Investigations in rabbits showed that the concentration of
micafungin in the kidney was similar to the concentra-
tion found in plasma [50]. On the other hand, the lack of
reports describing therapy failure when using micafungin
for candiduria could be the result of publication bias.
High-quality evidence is still poor, and guidelines, such
as the recent Infectious Diseases Society of America
(IDSA) guideline, do not recommend the use of
echinocandins for the treatment of urinary tract infec-
tions due to Candida species [6].
Other compartments where micafungin concentrations
have been measured are wound tissue (T/P ratio of 0.46)
[46], bile fluid (T/P ratio of 1.25) [31], and pancreatic
pseudocyst fluid [30]. In the latter, only one sample was
measured 24 h after a dose that contained 0.38 lg/mL,
but no dose or plasma concentration was reported [30].
2.4 Metabolism
Micafungin undergoes metabolism to at least 11 com-
pounds (M1–M11). It is the main circulating compound,
but also M1 (catechol form), M2 (methoxy form of M1)
and M5 (hydroxylation at the side chain) have been
detected in plasma. Both M1 and M2 are pharmacolog-
ically active metabolites, with an exposure of up to 11
and 2%, relative to the parent compound [26]. The M1
metabolite is produced by arylsulfatase and is further
metabolized to M2 by catechol-O-methyltransferase [51].
All other metabolites are thought to be inactive. The
main inactive metabolite is M5, with an exposure of
9–14% relative to the parent compound; this metabolite
is formed mainly by cytochrome P450 (CYP) 3A4 but
also by several other CYP isoenzymes (CYP1A2, 2B6,
and 2C). Like the parent drug, all metabolites show
linear PK [26].
2.5 Elimination
Systemic CL after infusion is approximately 12 mL/h/kg,
which is 840 mL/h for a 70 kg adult individual. t is
14–15 h and is independent of the dose. The main
metabolite, M5, has a half-life of 32 h. Excretion of
micafungin and its metabolites was investigated in two
mass balance studies, each with six subjects, with a col-
lection period of 169 h and 28 days, respectively. After
28 days, a total of 83% of the administered dose was col-
lected, 71% in the feces and 12% in urine. The distribution
of metabolites in these excretion fluids was not reported.
The mean t for all metabolites was estimated on 340 h
[15].
2.6 Variability Between Patients
The effects of intrinsic factors on the PK of micafungin
have been investigated in several large studies. No signif-
icant differences were found between sex, race, and age,
with, for the latter covariate, a group of 66- to 78-year-olds
being compared with a group of 20- to 24-year-olds. No
differences were found in Cmax, AUC, t, Vd, CL, and
percentage protein binding between these groups
[1, 15, 17, 26, 52]. Weight was found to explain a large
proportion of variability in CL in a group of 64 hematology
patients receiving a dose ranging from 12.5 to 200 mg/day.
Patients weighing less than 66.3 kg were found to have a
higher average AUC24 of 121 mg h/L, compared with
81 mg h/L in patients weighing more than 66.3 kg [53].
Furthermore, micafungin plasma concentrations in a
230 kg patient were approximately 50% lower compared
with a group of hematology patients with a mean weight of
82.6 kg [18, 54].
In a study of three groups of healthy volunteers with
body mass indexes (BMIs) of\25, 25–40, and[40 kg/m2,
the effect of weight on the CL of subjects [66 kg was
described by the function CL (L/h) = 1.04 9 (weight/
66)0.75 [55, 56]. This relation seems to conflict with the CL
found in healthy subjects in other reports (see Table 1). For
example, Hebert et al. reported a mean CL of 10 mL/h/kg
in subjects with a mean weight of 71.7 kg, thus having a
CL of 0.717 L/h [21]. According to the formula, these
subjects should have had a mean CL of 1.10 L/h, which is
an overestimation by more than 50%. This questions the
validity of a general formula using weight above a certain
cut-off, without taking into account physiological changes
that are associated with obesity [57].
2.7 Population PK Models
The plasma concentrations of micafungin and covariates
influencing the concentration have been investigated in 15
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population PK models (see Table 2 for details)
[38, 41, 45, 47, 52, 53, 55, 58–65]. In all cases, the plasma
concentration was best described using a two-compartment
model; additional compartments were used to explain tis-
sue concentrations in two studies [41, 47]. In the majority
of the models, weight was incorporated to explain vari-
ability in systemic CL, and, in approximately half of the
models, weight was also able to explain variability in Vd of
the central compartment. Interestingly enough, with the
exception of BMI, no other weight-derived covariates such
as fat-free mass, normalized fat mass, or lean body weight
have been investigated to explain variability in CL or
volume. Other covariates explaining variability in systemic
CL were platelet count in Japanese adults and pediatric
patients [52], alanine transferase and total bilirubin in
pediatric patients [58], the ratio of aspartate transaminase
and alanine transaminase in preterm neonates [38], and,
finally, albumin and Sequential Organ Failure Assessment
(SOFA) score in critically ill patients [61]. Variability in
volume in distribution was explained by albumin concen-
trations in both postsurgical patients with peritonitis and
critically ill patients [47, 61].
2.8 Interactions
Micafungin is metabolized partly by the liver through
various enzymatic systems, as described above [1]. Mica-
fungin is not a substrate for P-glycoprotein [9]. It has been
demonstrated in vitro that micafungin is a strong inhibitor
of a wide variety of efflux pumps [66]. As a perpetrator
drug, it has been demonstrated that micafungin influences
the CL of the following drugs: sirolimus, nifedipine and
itraconazole. A mechanistic basis for these interactions is
not provided in the Summary of Product Characteristics
(SmPC) but possibly due to inhibition of CYP3A4. As
increases in AUCs of sirolimus, nifedipine, and itracona-
zole have been found to not be clinically relevant (in-
creases of 21, 18, and 22%, respectively), they do not
warrant dose adaptations of the victim drug
[1, 18–20, 22, 23, 67–69]. Coadministration of micafungin
with amphotericin B deoxycholate leads to an increase in
amphotericin B exposure of 30%, accompanied by the
occurrence of more side effects [70], while micafungin
remains unaffected. Patients receiving this combination
should be monitored closely for (renal) side effects.
2.9 Safety
Micafungin acts by selective inhibition of the fungal
enzyme that produces the cell wall polymer 1,3-b-D-glucan
synthase. As human cells do not contain this polymer, a
favorable toxicity profile can be expected through the
absence of a direct pharmacological effect. Indeed, no
dose-limiting toxicity has been reported up to a daily dose
of 8 mg/kg (896 mg) for 1–4 weeks in adults [71]. Fur-
thermore, one patient was described as receiving 1400 mg
every other week for 12 weeks without any side effects
associated with micafungin [72]. In addition, a newborn
was accidently treated with a single 16 mg/kg dose of
micafungin without any adverse reactions [1]. The most
common side effects associated with micafungin are diar-
rhea, nausea, vomiting, pyrexia, thrombocytopenia, and
headache [15]. The European Medicines Agency, but not
the US FDA, issued a black-box warning for possible
development of foci of altered hepatocytes (FAHs) and
hepatocellular tumors as preclinical data indicated these
tumors developed in rats treated with high-dose micafungin
for 13 weeks [1]. After treatment discontinuation, the rats
recovered for 13 weeks but the FAHs were still present. At
least a part of these foci was not reversible [9]. The rele-
vance of the hepatocarcinogenic potential for use in
humans is unknown. As of today, no cases have been
published reporting this effect in humans.
3 Special Populations
The PK parameters of the below-described populations are
summarized in Table 3.
3.1 Hepatic Impairment
The effect of hepatic impairment was investigated as part
of the registration studies in eight volunteers with moderate
hepatic impairment due to hepatitis C, primary biliary
cirrhosis, or alcohol abuse, with Child–Pugh scores ranging
between 7 and 9. Exposure after a single 100 mg dose was
decreased to a mean of 98 mg h/L, versus 126 mg h/L in
matched healthy volunteers [21]. Similar results were
found in a study of eight subjects with severe hepatic
impairment who had an exposure of 100 versus 142 mg h/
L in eight matched healthy controls [24]. A possible
explanation can be found in decreased levels of albumin,
resulting in an increased free fraction of micafungin
[21, 24]. This results in a lower total plasma concentration
and explains the decrease in AUC. Nevertheless, this
decreased AUC is not considered to be clinically relevant
and no dose adjustments are recommended for patients
with moderate or severe hepatic dysfunction. Similar
results were observed in 34 liver transplant recipients
reported in three studies, with one patient being a
remarkable exception [73–75]. This patient had a small-
for-size graft liver with a volume of only 26% of a standard
liver, and showed a normal half-life of 16 h after a 50 mg
dose. However, after administration of a 100 mg dose, the
half-life increased to 76 h and the AUC12 of this patient
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increased from 79 to 601 mg h/L, corresponding to an
AUC after a 1000 mg dose in a healthy subject [75].
3.2 Renal Impairment
Although micafungin is not cleared renally, patients who
suffer from renal impairment might have altered PK due to
alterations in albumin concentrations available for protein
binding. The effect of renal impairment on the PK of
micafungin was investigated in nine patients with a crea-
tinine CL below 30 mL/min after a single dose of 100 mg,
and compared with nine matched healthy subjects. No
differences in AUC?, CL, Vd, half-life, Cmax, and protein
binding were observed between groups [15, 21]; therefore,
no adjustments are necessary for patients with renal
dysfunction.
3.3 Extracorporeal Elimination Techniques
The use of extracorporeal elimination techniques can
influence the PK of drugs by increasing the Vd, direct
elimination and adsorption to membranes and tubing
material. Micafungin is a large molecule that is highly
protein bound and not renally cleared. Indeed, no changes
in PK were observed in ten critically ill patients treated
with micafungin 100 mg daily during continuous venove-
nous hemofiltration (CVVH) using polyethersulfone or
polysulfone hemofilters. Samples at seven timepoints pre-
and postfilter were taken, and removal of micafungin was
not observed. In addition, in samples taken from the
ultrafiltrate, micafungin levels were below the limit of
quantification [63]. In a study of four patients receiving
CVVH using cellulose triacetate hollow fiber, the same
results were observed [73]. Furthermore, a similar study
observed no changes in pre- versus postfilter micafungin
concentrations in four critically ill patients treated daily
with 150–300 mg during continuous venovenous hemodi-
afiltration (CVVHDF) using a hollow-fiber membrane
composed of polymethyl methacrylate. In addition, these
patients were compared with nine critically ill patients not
receiving CVVHDF. Although interindividual variability
in CL was large throughout both groups, no indication of a
difference in CL or Vd was observed [76]. Dose adjust-
ments of micafungin are not indicated in these patients.
3.4 Critically Ill Patients
Changes in micafungin PK in critically ill patients in the
intensive care unit (ICU) have been investigated in two
prospective studies totaling 119 ICU patients. The first
study investigated micafungin concentrations over a
14-day period, with daily trough samples and intensive
sampling at day 3 and limited sampling on day 7 in 20 ICU
patients receiving micafungin 100 mg daily. At days 3 and
7, the AUC24 was 79 versus 66 mg h/L (no significant
difference) [77]. These exposures are much lower than the
exposure found in healthy volunteers (Table 1; mean
value = 133 mg h/L). Investigations in another study of 99
ICU patients confirmed this and found an AUC? ranging
between 65.5 and 99.5 mg h/L, depending on SOFA score,
albumin concentration, and bodyweight as relevant
covariates [61]. The lowest exposure of 65.5 mg h/L was
found in patients with a SOFA score of\10 and an albu-
min of B25 g/L. This study also showed that micafungin
PK were not influenced by using extracorporeal membrane
oxygenation (ECMO), confirming a report in a previously
described patient [78]. One of the reasons for lower
exposure might be the availability of albumin for protein
binding. A second reason is the influence of the SOFA
score on micafungin PK, which may impact the metabolic
routes of a drug. In the case of micafungin, an induction of
arylsulfatase, catechol-O-methyltransferase or CYP isoen-
zymes, or a change in biliary excretion, may be anticipated
[61, 77]. The lower AUC decreases the probability of target
attainment (PTA) when the licensed micafungin 100 mg is
used in ICU patients. Simulations show that only 62% of
patients reach the MIC/AUC target for non-C. parapsilosis
spp.; therefore, these patients could benefit from a dose
escalation to micafungin 200 mg, as indicated in the
manufacturer’s label information [62].
3.5 Burn Patients
Critically ill patients with thermal injuries showed a low-
ered plasma concentration of micafungin after a daily 100
mg dose, with a mean C24h of 0.9 mg/L compared with
approximately 2 mg/L in healthy volunteers [40]. Two case
series report that patients treated with micafungin
200–300 mg had comparable plasma concentrations com-
pared with healthy volunteers receiving 75 mg [42, 43].
Factors causing lower exposure in this patient population
are similar to those in general ICU patients. An additional
factor for the lower exposure might be the hypermetabolic
state, a phase occurring beyond 48 h after the injury period
for up to another 48 h, and also seen with other antifungals
in severely burned patients [79]. PK in burn patients were
compared with PK in patients with complicated intra-ab-
dominal infections, and data from both populations were
used to build a population PK model. No differences in PK
between these groups were observed, except for the rate
constant describing the distribution of micafungin between
blood plasma and tissue fluid. The authors concluded that
these populations should not be dosed differently from
each other. Simulations showed that a micafungin dose of
100–150 mg should be sufficient to achieve a PK/PD target
in plasma for non-C. parapsilosis spp. and C. parapsilosis
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species, with MIC values up to 0.008 and 0.064 mg/L,
respectively. A licensed dose of 200 mg was found to be
sufficient to achieve the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) susceptibility
target for C. albicans (0.016 mg/L), but not for C. glabrata
(0.03 mg/L) [41].
3.6 Hematology Patients
Hematology patients show different PK of micafungin
compared with healthy subjects. PK in hematology patients
has been investigated in a dose-escalation study of 62
patients treated with micafungin 12.5–200 mg/day (see
Table 3 for a summary of the PK parameters). AUC? was
81.1 mg h/L after the first 100 mg dose, and seems lower
compared with healthy subjects (Table 2; 133 mg h/L). CL
was higher being 13.6 mL/h/kg versus 10.4 mL/h/kg in
healthy subjects, but Vd seems to be in the same range as
healthy subjects, both approximately 0.2 L/kg. The half-
life of micafungin in hematology patients is short, 13 h
versus 15.4 h in healthy subjects [18].
4 PK in Pediatric Patients
The PK parameters found in neonates, children, and ado-
lescents are summarized in Table 4.
4.1 Neonates
PK of micafungin in premature neonates with a weight
above and below 1 kg has been investigated in four small
studies, with doses ranging from 0.75 to 15 mg/kg
[64, 80–82]. Initial investigations started with single doses
of 0.75 and 1 mg/kg, and showed that the average CL was
up to tenfold higher in neonates \1 kg compared with
healthy adults, i.e. 79.3–98 versus 10.4 mL/h/kg [80, 81].
The reported average half-life was 5.5 and 6.3 versus
15.4 h in healthy adults [80, 81]. Subsequently, higher
doses were investigated at steady state in the\1 kg pop-
ulation, with a dose of 10 and 15 mg/kg. CL was approx-
imately 36 mL/h/kg, still almost fourfold higher than CL in
healthy adults [64, 82]. AUC24 at steady state after a daily
10 mg/kg dose was 308 mg h/L, and proportionally higher
after a daily 15 mg/kg dose, with an AUC24 of 472 mg h/
L; both doses were well-tolerated [64, 82]. The reported
volumes of distribution in this select population have a
wide range, with averages ranging between 0.51 and
0.81 L/kg, which is at least 2.5-fold higher than the 0.2 L/
kg found in healthy adults [64, 80–82]. The high variability
in both Vd and CL between the reported populations
investigating PK at a very low dose of 0.75–1 mg/kg might
be due to non-linear kinetics in this patient population;
however, data are very sparse and this could also be an
artifact due to small sample sizes.
In premature neonates with a weight above 1 kg, a dose
range of 0.75–15 mg/kg has been investigated and seems to
show dose proportionality of AUC [64, 80–82]. The CL of
approximately 39 mL/h/kg found in this group was similar
to neonates with a weight below 1 kg [64, 80, 82]. The Vd
seems a bit lower in the [1 kg group, at 0.4 L/kg
[64, 80, 82]. In the study by Kawada et al., the PK
parameters reported in neonates[1 kg are conflicting with
the above-stated parameters . Here, an augmented CL of 81
(versus 39 mL/h/kg) and a Vd of 0.72 L/kg (versus
approximately 0.4 L/kg) was found; however, these dif-
ferences between data were explained by the study design.
Kawada et al. performed their investigations in a neonatal
population with a gestational age of 24–34 weeks within
12–24 h after birth, while Heresi et al. studied the same
population, but 3–8 weeks after birth [81].
Overall, neonates have a higher CL than healthy adults,
which can be explained by the fraction of unbound mica-
fungin. Yanni et al. found that the fraction of unbound
micafungin can be eightfold higher in neonates compared
with adults, suggesting an age-dependent serum protein
binding [83]. This explanation would discourage a dose
increase because it would mean that although the total
exposure decreases, the concentration of unbound mica-
fungin is not necessarily lowered. Lower total exposure can
additionally be caused by increases in intrinsic CL due to,
for example, maturation. Nevertheless, a dose of
10–15 mg/kg/day was well-tolerated, and reported hepatic
toxicity was reversible and manageable by monitoring
hepatic markers [38].
4.2 Children and Adolescents
PK of micafungin in children and adolescents has been
extensively investigated, with reports of a variety of age
and dose ranges, both after a single dose and in steady-state
conditions [51, 84–88]. This heterogeneity in study designs
complicates the comparison between studies. Table 4
summarizes the main PK parameters.
Both single dose and steady-state parameters show dose
proportionality and linearity for C24h, Cmax, and AUC
throughout a dose ranging 0.5–4.5 mg/kg [51, 86]. The
main PK parameters, i.e. half-life (approximately 13 h),
CL (approximately 19 mL/h/kg), and Vd (0.3 L/kg), did not
change throughout dose cohorts or time. Compared with
healthy adults, CL is almost twofold higher in children and
adolescents compared with adults (19.2 versus 10.4 mL/h/
kg), and the remarkably high CL seen in neonates seems to
decrease with age. This has been confirmed with a pairwise
comparison in a population ranging between 2 and
17 years of age, in children below and above 8 years of
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age. The group aged\8 years had a higher CL and Vd, i.e.
23.1 versus 17.1 mL/h/kg, and 0.35 versus 0.28 L/kg [86].
Albano et al. investigated these differences in more detail
and found that children aged from 4 months to 5 years
have a much higher CL at steady state of approximately
20 mL/h/kg, versus approximately 13 mL/h/kg in children
aged 6–16 years [84]. Vd in this group was also higher
(0.32 L/kg versus 0.26 L/kg) [84]. These changes in PK
throughout the processes of maturation and growth urge the
need for a higher weight-corrected dose compared with
adults, especially in children less than 8 years of age. The
role of protein binding remains unresolved as an explana-
tion of this variability. Furthermore, critically ill children
were shown to have an additionally increased CL of
41 mL/h/kg and an increased Vd of 0.64 L/kg, and should
receive an even higher dose than the registered 1–4 mg/kg
dose. After a 4 mg/kg dose, these children had an AUC of
117 mg h/L, which approximately corresponds to the AUC
in a child after a 2.5 mg/kg dose. A dose increase of
2.5–5 mg/kg should be considered in critically ill children
[89].
5 Pharmacodynamics
A limited number of studies investigating the relationship
between PK and efficacy or toxicity have been performed
in humans. The index best describing the PK/PD relation
for Candida infections is the (free) AUC/MIC ratio
[90–92]. For Aspergillus infections, no such relationship
has yet been identified.
To our knowledge, only one study has been performed
linking AUC/MIC ratios with clinical outcome. Andes
et al. evaluated a large cohort of patients with invasive
candidiasis or candidemia from phase II and III trials
(n = 493) on PK, MIC of the pathogen, and clinical out-
come (mycological and clinical success rate) [90]. They
found a significant relationship between mycological suc-
cess and AUC/MIC ratio for all Candida species; patients
with AUC/MIC ratios [3000 to B12,000 had a higher
percentage of mycological success than patients with AUC/
MIC ratios B3000 and [12,000 (98.0, 85.1, and 88.1%,
respectively). For C. parapsilosis, an AUC/MIC ratio
breakpoint above 285 was suggested for mycological suc-
cess [90]. Based on the abovementioned targets, a recent
simulation in critically ill patients receiving a standard dose
of 100 mg intravenously demonstrated that the PTA was
high for organisms with an MIC up to 0.016 mg/L, but
significantly decreased for attenuated MICs of 0.032 and
above [62]. Since microbiology results usually take several
days, these data support an empirical dose increase to 150
or 200 mg to cover the complete spectrum of susceptible
species (including those with attenuated MICs). An
argument to use the recommended 100 mg dose follows
the findings of Pappas et al. who demonstrated non-infe-
riority of micafungin 100 mg compared with 150 mg [93].
6 Conclusions and Future Perspective
Micafungin has been shown to be an effective drug for
the treatment and prophylaxis of candidiasis and can-
didemia. It shows predictable linear PK over a wide dose
range of 0.15–8 mg/kg in both adults and children. The
studies discussed in this review show the importance of
PK investigations in special populations as patient-
specific factors influence micafungin PK, showing that
most critically ill patients are reported to have decreased
exposure to micafungin, which might have consequences
for efficacy. The importance of low exposure might not
be relevant for infections with species with an MIC
below 0.016 mg/L, but might become more important in
the setting were the MIC of the offending organism is
above 0.016 mg/L.
It is clear that the PK of micafungin have been exten-
sively investigated, especially in adult hematology patients,
children, and also, recently, ICU patients. As with many
drugs, the PK are poorly characterized in (preterm) neo-
nates, mainly due to difficulties in performing clinical trials
in this population. Although micafungin is the most
extensively investigated of the three echinocandins, there is
still much knowledge to gain. Specifically, the rapid
change in (apparent) CL in the first few months after birth
and the relation to changes in the fraction of protein-bound
micafungin needs further investigation. In addition,
knowledge in this area can be used to develop tailor-made
dosing regimens. Currently, one trial is comparing the
efficacy of micafungin versus fluconazole in premature
neonates with candidiasis (ClinicalTrials.gov identifier:
NCT02145832).
There is an increasing interest in extending dose inter-
vals from once daily to every other day, and even once
every 2 weeks has been reported [72], mainly because of
micafungin’s favorable toxicity profile and the possible
post-antifungal effect. Extending the dose interval will also
allow patients to be ambulatory, improve quality of life,
reduce hospital costs, and lower the need and frequency of
accessing the central venous catheter [72]. In neutropenic
mice with invasive candidiasis, a single high dose of
micafungin was able to identically lower the fungal burden
as the same cumulative dose administered twice weekly
[72]. In children, this was investigated in a prophylactic
setting with 21 children, who had a mean age of 9 years,
receiving a 3–4 mg/kg dose twice weekly [94]. This ther-
apy was well-tolerated with no reported breakthrough
infection. An intermittent dosing strategy in adults with a
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high risk of fungal infection using a twice-weekly dose of
300 mg is ongoing (ClinicalTrials.gov identifier:
NCT02172768). However, as yet, no prospective trials
could be found comparing these strategies in humans with
invasive candidiasis.
We recommend that future research should focus on
three aspects:
First, we see a knowledge gap in the effect of protein
binding of micafungin in subpopulations with a reported
lower exposure to micafungin, such as neonates, chil-
dren, burn patients, ICU patients, and obese patients.
The effect of changes in the free fraction of any drug are
well known: a lower total concentration, a higher
apparent CL, and an unchanged concentration of
unbound, active drug. An increased awareness of the
effect of albumin concentrations would eventually result
in a better interpretation of PK and PD changes.
Second, we recommend using an MIC-based dosing
approach. We propose using a stratified approach were
the MIC of the offending pathogen drives the dose
selection. In the setting of a pathogen with an attenuated
MIC, higher exposure than achieved with regular dosing
regimens is needed, and an adaptive, individualized
approach might be of value.
Third, for determination of markers that can be used to
monitor therapy, the most obvious candidate is 1,3-b-D-
glucan. A PD marker might accelerate the investigation
into pharmacokinetic-pharmacodynamic (PK-PD) tar-
gets, which are mostly lacking, although micafungin is
the only echinocandin where a PK–PD target has been
identified to predict therapy success in humans. PK–PD
targets for both prophylactic and treatment purposes
would be most welcome. These targets can then be used
to improve treatment in children and adults, and
specifically investigate alternate dosing strategies that
are not only more patient friendly but might also have a
higher rate of therapy success.
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